Status
Conditions
Treatments
About
This is a randomized controlled trial that will be preceded by a safety trial focusing on the safety and efficacy of robotic telesurgery. The hypothesis is that robotic telesurgery has a non-inferior primary endpoint event rate to local laparoscopic surgery.
Full description
First, a safety run-in trial for robotic telesurgery will be conducted and evaluated according to "3+3 design". At least 3 patients of each cancer type (including liver cancer,renal cancer and rectal cancer) will be enrolled for robotic telesurgery. If there is a tumor type for which the prior safety trial is terminated, the subsequent randomized controlled trial will not include patients of that type.
Second, after passing the safety run-in trial, a randomized controlled trial will be performed. New patients with each cancer type who met the enrollment criteria will be randomly assigned to either the laparoscopic surgery group(control group) or the robotic telesurgery group (intervention group) (84 patients in each group, 168 patients in total) in a 1:1 two-group parallel design.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Liver Cancer:
Renal cancer:
Rectal cancer:
Exclusion criteria
Liver Cancer:
Renal cancer:
Rectal cancer:
Primary purpose
Allocation
Interventional model
Masking
177 participants in 2 patient groups
Loading...
Central trial contact
Kuang Ming, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal